Josipa Raguz, Catarina Pinto, Theresa Pölzlbauer, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, Valentin Just, Sarah Schmidt, Katell Bidet Huang, Felix Stemeseder, Timo Schippers, Ethan Stewart, Jakub Jez, Pedro Berraondo, Klaus K Orlinger, Henning Lauterbach
BACKGROUND: Engineered arenavirus vectors have recently been developed to leverage the body's immune system in the fight against chronic viral infections and cancer. Vectors based on Pichinde virus (artPICV) and lymphocytic choriomeningitis virus (artLCMV) encoding a non-oncogenic fusion protein of human papillomavirus (HPV)16 E6 and E7 are currently being tested in patients with HPV16+ cancer, showing a favorable safety and tolerability profile and unprecedented expansion of tumor-specific CD8+ T cells...
April 17, 2024: Journal for Immunotherapy of Cancer